SCHEMBL15207207

SCHEMBL15207207

COc1cc(Nc2nc3c(-c4ccc(C)cc4)nccn3n2)cc(OC)c1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FLT1 P17948 1/20 0.45
FLT4 P35916 1/20 0.45
KDR P35968 1/20 0.45
ALDH1A1 P00352 2/20 0.43
GAA P10253 2/20 0.43
MAPT P10636 2/20 0.43
GFER P55789 1/20 0.43
KDM4E B2RXH2 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
JAK2 O60674 13/20 0.43
PTK2 Q05397 11/20 0.43
JAK3 P52333 6/20 0.43
SYK P43405 2/20 0.40
SRC P12931 1/20 0.40
ZAP70 P43403 1/20 0.40
CDK2 P24941 1/20 0.39
GSK3B P49841 1/20 0.39
EIF2AK4 Q9P2K8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19086 0.93 JAK2 (0.47) FLT1FLT4KDRALDH1A1GAA
SCHEMBL19799 0.90 JAK2 (0.43) FLT1FLT4KDRJAK2PTK2
SCHEMBL19738 0.90 KDR (0.53) FLT1FLT4KDRALDH1A1JAK2
SCHEMBL21584 0.90 FLT1 (0.44) FLT1FLT4KDRJAK2PTK2
SCHEMBL15207013 0.89 BRD4 (0.47) ALDH1A1GAAMAPTGFERKDM4E
SCHEMBL19281 0.88 KDR (0.41) FLT1FLT4KDRJAK2PTK2
SCHEMBL20465 0.87 KDR (0.43) FLT1FLT4KDRGAAMAPT
SCHEMBL20556 0.86 JAK2 (0.50) FLT1FLT4KDRJAK2PTK2
SCHEMBL20985 0.86 ZAP70 (0.48) JAK2PTK2JAK3SYKZAP70
SCHEMBL15207893 0.85 SYK (0.43) FLT1FLT4KDRJAK2PTK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2609098-B1 TRIAZOLOPYRAZINE DERIVATIVES MERCK PATENT GMBH (DE) 2016-07-13 EP disclosed
US-9023851-B2 Triazolopyrazine derivatives MERCK PATENT GMBH (DE) 2015-05-05 US disclosed
US-9023851-B2 Triazolopyrazine derivatives MERCK PATENT GMBH (DE) 2015-05-05 US disclosed
US-9023851-B2 Triazolopyrazine derivatives MERCK PATENT GMBH (DE) 2015-05-05 US disclosed
US-20130225568-A1 TRIAZOLOPYRAZINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed
US-20130225568-A1 TRIAZOLOPYRAZINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed
US-20130225568-A1 TRIAZOLOPYRAZINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225568-A1 TRIAZOLOPYRAZINE DERIVATIVES SYK, IRAK1, ZAP70 FLT1 47/4885FLT4 174/4885KDR 242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.